comparemela.com

Latest Breaking News On - Sukumar nagendran - Page 1 : comparemela.com

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Initiation of REVEAL pediatric trial in the U.S.broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Ret.

United kingdomUnited statesUniversity medical centerElizabeth berry kravisSukumar nagendranCarolyn hawleyHayleigh collinsCompany contactExchange commissionTaysha gene therapies incHead of corporate communicationsCanale communicationsEuropean commissionRegulatory agencyUt southwestern gene therapy programUnited statesbroadens

Rett syndrome gene therapy trial expanded to include patients aged 12 years and older

Rett syndrome gene therapy trial expanded to include patients aged 12 years and older
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Shenaz baghaSukumar nagendranHealth canadaTaysha gene therapies inc

Taysha Gene Therapies, Inc (NASDAQ:TSHA) Q3 2023 Earnings Call Transcript

Operator: Good afternoon and welcome to the Taysha Gene Therapies Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

United kingdomUnited statesKristen kluskaKamran alamSukumar nagendranCanaccord genuitySean nolanWhitney ijemHayleigh collinsTaysha gene therapies incCantor fitzgeraldData monitoring committeeHead of corporate communicationsEuropean commissionSilicon valley bankExchange commission

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly e.

United kingdomUnited statesCarolyn hawleyElsa rossignolHayleigh collinsSukumar nagendranTaysha gene therapies incRegulatory agencyDrug administrationCompany contactHead of corporate communicationsCanale communicationsEuropean commissionUt southwestern gene therapy programData monitoring committeeExchange commission

Investigational Gene Therapy for Rett Syndrome Gets Fast Track Status

The FDA has granted Fast Track designation to TSHA-102, an AAV-based gene therapy, for the treatment of Rett syndrome.

Sukumar nagendranDrug administrationFast track

vimarsana © 2020. All Rights Reserved.